Sugi Predict

Sugi Predict / Compounds / SCHEMBL16248689

SCHEMBL16248689

SCHEMBL16248689

OCCCOCC(COCCCO)(COCCCO)COCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ TSHR P16473 1/20 0.47
▸ LTA4H P09960 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ CA1 P00915 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ HRH4 Q9H3N8 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ GBA1 P04062 2/20 0.37
▸ UGCG Q16739 2/20 0.37
▸ GBA2 Q9HCG7 2/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26510423 0.97 KDM4E (0.50) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL22912637 0.95 KDM4E (0.47) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL16248683 0.95 KDM4E (0.47) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL19437614 0.95 KDM4E (0.47) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL23332602 0.94 KDM4E (0.47) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL22912633 0.94 KDM4E (0.47) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL19437656 0.93 L3MBTL1 (0.47) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL22227353 0.92 KDM4E (0.45) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL22838215 0.88 KDM4E (0.42) KDM4EPOLBTSHRLTA4HEPHX2
SCHEMBL18961750 0.85 KDM4E (0.49) KDM4EPOLBTSHRLTA4HEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357776-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-11-09 — — US disclosed
US-20230357776-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-11-09 — — US disclosed
US-20230321226-A1 SYNTHETIC ARCHAEAL DIETHER LIPIDS APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS) (FR) 2023-10-12 — — US disclosed
US-11732265-B2 Compositions and methods for modulating complement factor B expression IONIS PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-11732265-B2 Compositions and methods for modulating complement factor B expression IONIS PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
EP-4219718-A2 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION Ionis Pharmaceuticals, Inc. (US) 2023-08-02 — — EP disclosed
US-20230151365-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-05-18 — — US disclosed
US-20230151365-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-05-18 — — US disclosed
US-20230057718-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-02-23 — — US disclosed
US-20220324900-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2022-10-13 — — US disclosed
US-9181550-B2 Compositions and methods for modulating apolipoprotein (a) expression ISIS PHARMACEUTICALS, INC. (US) 2015-11-10 — — US disclosed
US-20150315594-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-11-05 — — US disclosed
US-9163239-B2 Compositions and methods for modulating apolipoprotein C-III expression ISIS PHARMACEUTICALS, INC. (US) 2015-10-20 — — US disclosed
US-9145558-B2 Compositions and methods for modulating HBV expression ISIS PHARMACEUTICALS, INC. (US) 2015-09-29 — — US disclosed
US-9127276-B2 Conjugated antisense compounds and their use ISIS PHARMACEUTICALS, INC. (US) 2015-09-08 — — US disclosed
US-20150176007-A1 COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-06-25 — — US disclosed
US-20150126719-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 — — US disclosed
US-20150126718-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 — — US disclosed
US-20150126720-A1 COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 2015-05-07 — — US disclosed
US-20140343123-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE ISIS PHARMACEUTICALS, INC. (US) 2014-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321226-A1 SYNTHETIC ARCHAEAL DIETHER LIPIDS DDOST, ABHD16A, GMDS KDM4E 2833/4885POLB 1537/4885TSHR 4183/4885
US-20220324900-A1 COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION TEK, PLIN3, FABP3 KDM4E 3205/4885POLB 3569/4885TSHR 4267/4885
US-20230151365-A1 COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION TTR, GALNT1, GALNT3 KDM4E 3857/4885POLB 4492/4885TSHR 370/4885
US-20150176007-A1 COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION HAVCR2, HCCS, HDGF KDM4E 3550/4885POLB 1047/4885TSHR 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.